Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 11/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | AGXT | P21549 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL30914652 | 0.98 | TAAR1 (0.96) | TAAR1DRD2DRD1IDO1AGXT | |
| Hydrochloric Acid SCHEMBL5214116 | 0.98 | TAAR1 (0.96) | TAAR1DRD2DRD1IDO1AGXT | |
| SCHEMBL237142 | 0.87 | TAAR1 (0.77) | TAAR1IDO1AGXTCYP2A6HTR6 | |
| SCHEMBL4399626 | 0.85 | TAAR1 (0.74) | TAAR1IDO1AGXTSMN1; SMN2MAOB | |
| SCHEMBL6183551 | 0.85 | TAAR1 (0.74) | TAAR1IDO1AGXTMAOB | |
| Hydrochloric Acid SCHEMBL5234157 | 0.85 | TAAR1 (0.74) | TAAR1IDO1AGXTCYP2A6HTR6 | |
| SCHEMBL552962 | 0.84 | TAAR1 (0.71) | TAAR1IDO1AGXT | |
| SCHEMBL659100 | 0.83 | TAAR1 (0.70) | TAAR1DRD2DRD1HTR2ACYP2A6 | |
| SCHEMBL7199505 | 0.82 | TAAR1 (0.69) | TAAR1IDO1AGXTSMN1; SMN2MAOB | |
| SCHEMBL3401008 | 0.81 | TAAR1 (0.68) | TAAR1IDO1AGXTSMN1; SMN2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 914 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894363-B | Synthesis process of 6-bromo-1, 2,3, 4-tetrahydroisoquinoline | 苏州艾缇克药物化学有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-116444598-B | Ganoderic acid A derivative, its synthesis method and application in treating tumor | 中国医学科学院药用植物研究所 | 2024-11-01 | — | — | CN | claimed |
| CN-118813253-A | Preparation method of tin-based perovskite | 南京工业大学 | 2024-10-22 | — | — | CN | claimed |
| CN-115141197-B | 3-aromatic heterocycle substituted phenyl derivative and preparation method and application thereof | 安徽医科大学 | 2024-03-26 | — | — | CN | claimed |
| CN-116444598-A | Ganoderic acid A derivative, its synthesis method and application in treating tumor | 中国医学科学院药用植物研究所 | 2023-07-18 | — | — | CN | claimed |
| CN-115894363-A | Synthesis process of 6-bromo-1,2,3,4-tetrahydroisoquinoline | 苏州艾缇克药物化学有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115141197-A | 3-aromatic heterocyclic substituted phenyl derivative and preparation method and application thereof | 安徽医科大学 | 2022-10-04 | — | — | CN | claimed |
| CN-113512029-A | Preparation and application of substituted pyrazole compound containing pyrimidinamine | 沈阳中化农药化工研发有限公司 | 2021-10-19 | — | — | CN | claimed |
| CN-110002930-B | Method for hydrogenation reduction of alkenyl aromatic halogenated derivatives | 浙江大学 | 2020-05-12 | — | — | CN | claimed |
| US-8574953-B2 | Low temperature melt-processing of organic-inorganic hybrid | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2013-11-05 | — | — | US | claimed |
| US-20120126216-A1 | LOW TEMPERATURE MELT-PROCESSING OF ORGANIC-INORGANIC HYBRID | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-05-24 | — | — | US | claimed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | claimed |
| US-7291516-B2 | Low temperature melt-processing of organic-inorganic hybrid | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2007-11-06 | — | — | US | claimed |
| US-20060234480-A1 | Low temperature melt-processing of organic-inorganic hybrid | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2006-10-19 | — | — | US | claimed |
| US-7105360-B2 | Low temperature melt-processing of organic-inorganic hybrid | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2006-09-12 | — | — | US | claimed |
| US-20030170918-A1 | Low temperature melt-processing of organic-inorganic hybrid | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2003-09-11 | — | — | US | claimed |
| US-20260091147-A1 | METHOD FOR DETECTING INNATE IMMUNE ACTION IN VIVO USING GPR84-PET | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIV (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-5260316-A | Lipoxygenase inhibitor | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0526402-A1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA-GEIGY AG (CH) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | TAAR1 1680/4885DRD2 2531/4885DRD1 2490/4885 |
| US-20260091147-A1 | METHOD FOR DETECTING INNATE IMMUNE ACTION IN VIVO USING GPR84-PET | GPR84, GPR65, GPR88 | TAAR1 128/4885DRD2 316/4885DRD1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.